Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Jan Astermark, MD, PhD, John Schwarz, MA, Sharyne M. Donfield, PhD, Donna M. DiMichele, MD, Bruce M. Ewenstein, MD, PhD, Edward D. Gomperts, MD, George W. Nelson, PhD, Johannes Oldenburg, MD, PhD, Amy D. Shapiro, MD, Gerald Spotts, PhD, Cheryl A. Winkler, PhD, Erik Berntorp, MD, PhD

Blood (2009) 114 (22): 217.

https://doi.org/10.1182/blood.V114.22.217.217

Published: 2009

Journal Articles

Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A.

Jan Astermark, MD, PhD, Johannes Oldenburg, MD, PhD, Anna Pavlova, Erik Berntorp, MD, PhD, Ann-Kari Lefvert, MD, PhD, MIBS Study Group

Blood (2005) 106 (11): 212.

https://doi.org/10.1182/blood.V106.11.212.212

Published: 2005

Journal Articles

The FEIBA ® NovoSeven ® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

Erik Berntorp, MD, PhD, Sharyne Donfield, PhD, Jennifer Waters, JD, Eva Mattson, RN, Donna DiMichele, MD, Alessandro Gringeri, MD, PhD, Jan Astermark, MD, PhD

Blood (2005) 106 (11): 324.

https://doi.org/10.1182/blood.V106.11.324.324

Published: 2005

Journal Articles

Activation of the Coagulation System Should Be Considered in the Initial Phase of Chemotherapy in Acute Myeloid Leukemia.

Jan Astermark, MD PhD, Karin Strandberg, MD PhD, Bengt Sallerfors, MD PhD, Johan Stenflo, MD PhD, Erik Berntorp, MD PhD

Blood (2004) 104 (11): 1039.

https://doi.org/10.1182/blood.V104.11.1039.1039

Published: 2004

NARROW

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A.

The FEIBA ® NovoSeven ® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

Activation of the Coagulation System Should Be Considered in the Initial Phase of Chemotherapy in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A.

The FEIBA ® NovoSeven ® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

Activation of the Coagulation System Should Be Considered in the Initial Phase of Chemotherapy in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only